Ravasio R, Tiseo M, Pradelli L, Bellone M, Gervasi A, Coffani M. Cost-effectiveness analysis of alectinib versus crizotinib in first-line treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer. Grhta [Internet]. 2019 Jun. 13 [cited 2024 Nov. 24];6(1). Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/462